BAY 1143572

Drug Profile

BAY 1143572

Alternative Names: BAY1143572; PTEFb inhibitor

Latest Information Update: 01 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Positive transcriptional elongation factor B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Leukaemia

Most Recent Events

  • 01 Sep 2016 Bayer completes a phase I clinical trial in Cancer (Late-stage disease, Second-line therapy or greater) in Singapore, Korea, USA and Taiwan (NCT01938638)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical trial in Leukaemia presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 16 Oct 2015 Phase-I clinical trials in Cancer (Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top